Table 1.
Effect of hAFSCs on biochemical measurements (n=20/group)
| Group I negative control |
Group II cisplatin-treated |
Group III cisplatin+hAFSCs-treated |
Group VI Cisplatin+DMEM culture media treated |
||
|---|---|---|---|---|---|
| Sr.Cr. (mg/dl) | Day 4 | 0.40±0.12 | 1.92±0.03* | 1.02±0.08*,§ | 1.88±0.1*# |
| Day 7 | 0.37±0.12 | 1.61±0.05*,‡ | 0.85±0.08*,§,‡ | 1.63±0.03*,#,‡ | |
| Day 11 | 0.41±0.11 | 1.00±0.07*,‡,† | 0.70±0.06*,§,‡ | 1.02±0.1*,#,‡,† | |
| Day 30 | 0.39±0.10 | 0.77±0.03*,‡,†,• | 0.85±0.05*,§,‡ | 0.81±0.04*,#,‡,†,• | |
| BUN (mg/dl) | Day 4 | 18.6±1.14 | 85.6±1.67* | 34.4±1.14*,§ | 85.4±1.14*,# |
| Day 7 | 18.2±1.48 | 55.2±1.30*,‡ | 28.0±1.22*,§,‡ | 53.8±0.84*,#,‡ | |
| Day 11 | 17.2±1.48 | 32.3±1.48*,‡,† | 24.4±0.89*,§,‡,† | 32.4±1.51*,#,‡,† | |
| Day 30 | 18.0±1.58 | 26.4±0.55*,‡,†,• | 23.2±0.84*,§,‡ | 26.2±0.83*,#,‡,†,• | |
| Cr. Cl. (ml/min/100 gm) | Day 4 | 1.62±0.44 | 0.007±0.001* | 0.018±0.06* | 0.008±0.001*,‡ |
| Day 7 | 1.78±0.55 | 0.014±0.001*,‡ | 0.045±0.001*,§,‡ | 0.012±0.002*,#,‡ | |
| Day 11 | 1.86±0.56 | 0.050±0.01*,‡,† | 0.060±0.007*,‡,† | 0.050±0.013*,‡,† | |
| Day 30 | 1.76±0.55 | 0.360±0.17*,‡,†,• | 1.000±0.14*,§,‡,†,• | 0.460±0.26*,‡,†,• |
Significant difference compared to corresponding *control, §cisplatin group and #cisplatin+hAFSCs group.
Significant difference compared to intragroup ‡day 4, †day 7, •day 11 by one-way analysis of variance (ANOVA) followed by posthoc multiple comparisons (Scheffé test) at p≤0.05.